Moshe Rogosnitzky is founder of Adjuvant Medical Solutions, recognized for providing 14 years of personalized oncology consulting, utilizing highly specialized individual genomic diagnostics to outline ground-breaking treatment strategies.
A scientist and inventor, Rogosnitzky holds patents in the fields of Prostate Cancer, Crohn’s Disease, Dry Eye, Corneal Ulcers, and Hemostasis.
Rogosnitzky is the creator of LDNscience.org – the largest physician and patient public information site for Low Dose Naltrexone (LDN). He is responsible for initiating the development of LDN for treating Crohn's disease, with Phase 1 & 2 trials completed and licensed to TNI Biotech. He is a pioneer in developing new uses for existing drugs including treatments for eye disorders (Remedeye Inc.), as well as cancer (Primocure Pharma Inc). He continues to research and develop new treatments for cancer and chronic diseases.
His expertise across multiple cancer types has lead to his participation in several Champions Oncology VIP Expert Opinion Panel conferences including Pancreatic Cancer, Lung Cancer, Esophageal Cancer, Metastatic Melanoma, and Sarcoma.
Rogosnitzky consults to companies seeking his expertise in clinical development of secondary applications for existing approved drugs (off-label drug use).
He is regularly invited to lecture at conferences in North America and Asia, and has guest lectured for the Israeli Government Ministry of Health.
Rogosnitzky has long-established collaborations with researchers at academic institutions including Johns Hopkins University (Baltimore MD), University Hospital of Lille (France), Hershey Medical Center (Penn State University), Hadassah University Hospital (Jerusalem), St. George’s University Hospital (London), and University of Southern California.
In 2006, he founded the nonprofit MedInsight® Research Institute. MedInsight’s concise reviews of off-label drug uses has resulted in life-saving benefits for numerous patients worldwide.
Rogosnitzky has served as a peer reviewer for International Immunopharmacology (Elsevier), Molecules (MDPI), The Journal of Molecular Diagnostics (American Society for Investigative Pathology – ASIP), World Journal of Surgical Oncology (Springer), Fibrogenesis & Tissue Repair (BioMed Central) and Evidence Based Complementary & Alternative Medicine. He is also published in scientific literature in a variety of fields including inflammatory bowel disease (IBD), non-invasive cancer diagnostics, abdominal surgery, hemostasis and treatments for cancers of the prostate, breast, and skin.